MacroGenics
Pre-Approval PRO BETAPipeline by Phase
Therapeutic Focus
Clinical Trials (36)
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Started: 8/24/2015
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
Started: 9/1/2009
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Started: 5/1/2025
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
Started: 9/28/2023
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
Started: 6/13/2023
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
Started: 9/30/2019
Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer
Started: 3/1/2013
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
Started: 3/17/2021
Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
Started: 4/15/2008
Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck
Started: 10/1/2019
A Study of MGC028 in Participants With Advanced Solid Tumors
Started: 2/13/2025
A Study of MGC026 in Participants With Advanced Solid Tumors
Started: 3/6/2024
A Study of MGC030 in Participants With Advanced Solid Tumors
Started: 10/7/2026
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
Started: 7/13/2022
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
Started: 4/19/2022
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
Started: 7/1/2015
MGC018 With or Without MGA012 in Advanced Solid Tumors
Started: 11/21/2018
A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
Started: 9/26/2022
Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
Started: 1/1/2016
MGD019 DART® Protein in Unresectable/Metastatic Cancer
Started: 12/12/2018
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
Started: 6/9/2014
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
Started: 8/18/2017
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
Started: 9/25/2018
MGD009/MGA012 Combination in Relapsed/Refractory Cancer
Started: 2/27/2018
Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis
Started: 12/1/2009
MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer
Started: 6/4/2018
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
Started: 3/26/2015
Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma
Started: 10/1/2014
Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes
Started: 8/1/2010
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
Started: 12/1/2016
Tissue Procurement Substudy for Participants in Study CP-MGA271-01
Started: 7/1/2013